Purple Biotech (PPBT) Liabilities and Shareholders Equity (2014 - 2026)

Purple Biotech (PPBT) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $14.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.0 million (down 49.23% YoY) and the FY2025 annual result came in at $17.6 million, down 52.56% from the prior year.
• Liabilities and Shareholders Equity declined to $14.4 million in Q1 2026 per PPBT's latest filing, from $17.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $54.6 million in Q4 2022 and bottomed at $14.4 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $37.0 million (2024), against an average of $33.6 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity retreated 16.4%; it then slumped 52.56% in 2025.
• Tracing PPBT's Liabilities and Shareholders Equity over 5 years: stood at $54.6 million in 2022, then declined by 18.89% to $44.3 million in 2023, then dropped by 16.4% to $37.0 million in 2024, then tumbled by 52.56% to $17.6 million in 2025, then slipped by 17.95% to $14.4 million in 2026.
• Per Business Quant, the three latest PPBT Liabilities and Shareholders Equity figures stand at $14.4 million (Q1 2026), $17.6 million (Q4 2025), and $37.0 million (Q4 2024).

Peer Comparison